Rebalix
Franklin Templeton · sheet of 10 September 2026
Franklin Templeton · sheet of 10 September 2026ETF sheet · official issuer and register data
Franklin FTSE Asia ex China ex Japan UCITS ETF
FLQA · IE00BFWXDV39 · class SINGLCLASS · USD · domicile Ireland
Equity · Asia-PacificSFDR art. 6
Index tracked: FTSE Asia ex Japan ex China Index-NR
- TER
- 0.14%+ trans. 0.17%
- Fund size
- 521 m EUR
- Tracking difference
- −1.29%3-year avg
- 🇮🇹 tax rate
- 26.00%white list 0.00%
- Replication
- Physical (optimised)
- Income
- Accumulating
Launch 27 Sept 2018 · costs from the KID as of 2 Sept 2026 · 815 securities held · 10 venues (ESMA register)
The fund’s objective — in the issuer’s words
From the Key Information Document (KID) · 2 Sept 2026
Investment Objective To provide exposure to medium and large capitalisation companies in Asian markets, excluding China and Japan.
Investment Policy
The Fund invests in equities of Asian companies (excluding China and Japan) of medium and large market capitalisation that are included in the benchmark. The benchmark captures large and mid-sized companies from certain developed and emerging markets in Asia. Derivatives and techniques The Fund may use derivatives for hedging and efficient portfolio management. Strategy The investment manager seeks to…
Performance since series start (in euro) — base 100
30 Sept 2018 → 31 Jul 2026 · dividends reinvested where declared by the issuer · converted at ECB rates
Returns in euro
| 1 year | +59.7% |
| 3 years | +85.6% |
| 5 years | +86.6% |
| 10 years | series too young |
| Since series start | +112.0% |
Risk · 1 / 3 / 5 years
| Volatility (ann.) | 28.67% | 20.21% | 17.61% |
| Max drawdown | −18.15% | −19.61% | −25.26% |
| Sharpe | 1.74 | 1.18 | 0.69 |
| Sortino | 2.67 | 1.73 | 1.00 |
Sharpe/Sortino: risk-free = ECB MRO avg; nominal volatility
Rebalix · FLQA · IE00BFWXDV391
RebalixFLQA · IE00BFWXDV39 · sheet of 10 September 2026
Tracking difference — year by year
Fund minus index, complete calendar years · from issuer-declared series
| Year | Fund | Index | TD |
|---|---|---|---|
| 2025 | +30.16% | +31.61% | −1.45% |
| 2024 | +7.52% | +8.66% | −1.14% |
| 2023 | +12.89% | +14.18% | −1.29% |
| 2022 | −13.34% | −13.16% | −0.18% |
| 2021 | +4.61% | +5.07% | −0.46% |
Holdings
Portfolio as declared by the issuer · 26 Aug 2026 · 815 securities · top-10 weight = 45.4%
| Top holdings | Weight |
|---|---|
| 19.9% | |
| 9.4% | |
| 7.3% | |
| 2.0% | |
| 1.3% | |
| 1.2% | |
| 1.2% | |
| 1.1% | |
| 1.0% | |
| 1.0% |
Countries (% of fund)
Sectors (% of fund)
Listing venues
ESMA register (FIRDS) and official exchange lists
FLQA · Borsa Italiana (ETFplus), Euronext Paris
FVSJ · Börse Düsseldorf, Börse Frankfurt, Börse Hamburg, Börse Hannover, Börse München / gettex, Börse Stuttgart, Tradegate Exchange, Xetra (Deutsche Börse)
+ 19 unmapped venues (MTF, RFQ, professional)
Official documents
Clickable links in the PDF
The live sheet, always up to date
rebalix.com/en/etf/IE00BFWXDV39
Series, distributions, holdings and documents refresh daily.
rebalix.com/en/etf/IE00BFWXDV39
Series, distributions, holdings and documents refresh daily.
Sheet produced on 10 September 2026 · data as of the dates shown section by section. Sources: official issuer documents (KID, factsheet, NAV and total-return series, declared portfolio), ESMA register (FIRDS), European Central Bank (FX), Italian tax authority / issuer (white-list share). Public methodology: rebalix.com/en/methodology. “—” = not published by the source, never estimated.
Informational document generated by rebalix.com: facts only, no recommendations. Not investment advice or investment research under Directive 2014/65/EU (MiFID II), nor an offer or solicitation. Past performance is not indicative of, nor a guarantee of, future results; the value of an investment can go down as well as up. Before any decision read the issuer’s KID and Prospectus; tax treatment depends on individual circumstances. Trademarks and logos belong to their respective owners and only identify the instrument and its issuer: no affiliation, sponsorship or endorsement.
Rebalix · FLQA · IE00BFWXDV392